SELLAS Life Sciences Group (SLS) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Supernus Pharmaceuticals (SUPN) over the past year, gaining 495.3% versus a loss of 10.4%. Over five years, SUPN leads with a +36.0% price change compared with +28.1% for SLS. Supernus Pharmaceuticals is the larger company by market cap ($2.51 billion vs $2.28 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLS | SUPN |
|---|---|---|
| Share price | $11.31 | $43.05 |
| Market cap | $2.28B | $2.51B |
| 1-day change | -0.26% | +0.51% |
| YTD return | +200.00% | -13.38% |
| 1-year return | +495.26% | -10.44% |
| 5-year return | +28.09% | +35.98% |
| Forward P/E | — | 9.65 |
| EPS (TTM) | $-0.21 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $718.95M |
| Revenue growth (YoY) | — | +8.63% |
| Net income (latest FY) | — | $-38.55M |
| Gross margin | — | 89.63% |
| Operating margin | — | -8.66% |
| Net margin | — | -5.36% |
| 52-week high | $15.88 | $59.68 |
| 52-week low | $1.39 | $40.51 |
| Distance from 52-week high | -28.78% | -27.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +187.36% | +43.44% |
| Average volume | 6.56M | 766.52K |
| Shares outstanding | 201.95M | 58.22M |
| Employees | 13 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed SUPN by 505.7 percentage points over the past year.
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
SLS vs SUPN FAQ
Which is bigger, SELLAS Life Sciences Group or Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) is larger, with a market capitalization of $2.51B compared with $2.28B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, SLS or SUPN?
SLS returned +495.26% over the past 12 months, compared with -10.44% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are SELLAS Life Sciences Group and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.